Une candidature complète en une minute
Un CV et une lettre de motivation personnalisés, prêts à envoyer.
DBV Technologies seeks a Senior Director, Data Management to lead clinical data management and move core data collection and standards work in-house while upholding data quality and regulatory compliance.
You will oversee EDC build and SDTM configuration, work with Clinical, Biostatistics, Safety, and Regulatory teams, and direct CRO partners. The role requires deep hands-on data management experience and broad ownership as the function evolves.
The Senior Director, Data Management will lead clinical data management at DBV Technologies, a biopharmaceutical company developing treatments for food allergy. The role is responsible for moving core data collection and standards work, including EDC build and SDTM configuration, from external vendors to an internal team, while keeping data quality and regulatory requirements intact. You will work with Clinical, Biostatistics, Safety, and Regulatory colleagues, direct the data management work of our CRO partners, and build out the internal team. The position suits someone with deep hands-on data management experience who wants broad ownership of a function that is still taking shape.
Warren, New Jersey - minimum 3 days on site
$200-280k
DBV Technologies is a global clinical stage biopharmaceutical company founded by pediatricians who believed that food allergies could one day be treated safely and effectively.
We are on a mission to advance epicutaneous immunotherapy using our innovative technology platform, Viaskin, to develop treatment options for immunologic diseases with significant unmet medical need.
This mission drives our commitment to the advancement of treatments for patients and their families. That is why we are investigating a potential new class of immunotherapy, epicutaneous immunotherapy (EPIT), that aims to re-educate the immune system of patients through the skin.
Today, we are focused on exploring the use of Viaskin to address food allergies, a devastating condition that afflicts millions of patients. As an important milestone in our journey, we hope to offer the first epicutaneous immunotherapy treatment for peanut allergy.
Tomorrow, as pioneers, we will continue to explore the broad applications of this potential new class of immunotherapy, including treatments for patients suffering from inflammatory and autoimmune diseases.